Labiotech.eu

News and Trends 16 Apr 2015

Histalim, already 10 years committed to Histology

In the prestigious Fabre Museum of Montpelier (France), Thursday, April 9, 2015, Histalim organized for his birthday, an afternoon of table speeches around bioservices and also an evening with contemporary art exhibition and concert. Histalim, founded in June 2005, provides services around histology to different players in the pharmaceutical and medical industry and agri-food research. […]

April 16, 2015 - 5 minutesmins - By Cédric Brock

News and Trends 16 Apr 2015

The first-in-human Phase I trial for a treatment against glaucoma core

Isarna Therapeutics has initiated Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta (TGF-ß2) to treat advanced glaucoma. This first-in-human Phase I trial, conducted at the University Hospitals of Mainz and Tuebingen, Germany, is designed to evaluate the safety and long-term tolerability of ISTH0036 in patients with advanced glaucoma […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Wilson Therapeutics on its way to cure Wilson disease

Wilson Therapeutics has closed a €37.4M Series B financing to advance its late-stage development program for Wilson’s disease. The company will present its ongoing Phase II trial of WTX101-201, the company’s treatment for this disease, at the upcoming 50th International Liver Congress 2015. Approximately 1 in 15000 people worldwide have Wilson Disease, a rare genetic disorder that prevents the […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Yesterday, the company announced a €94M investment in its Berkeley (California) manufacturing site to build a product testing facility that will support the next generation of treatments for patients with hemophilia A. David […]

April 16, 2015 - 2 minutesmins - By Joachim Eeckhout

final sterilization proteins solution sanofi pasteur

News and Trends 16 Apr 2015

The challenge of terminal sterilization of Proteins

The production of biologicals is an important challenge for the industry. Today, very often, the only way to have a sterile final product is to, first, use sterile components and then, launch the production in a fully aseptic manufacturing facility. What if we could terminally sterilize the protein-based outcome once produced? More and more biologicals are brought to the market, […]

April 16, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Apr 2015

flash4science, the life science private shopping club

Any scientist knows how expensive purchasing new equipment can be. However, one platform, flash4Science, in particular caught our attention. The company located in Germany has set itself an interesting challenge as it tries to combine life sciences and private shopping together. Two domains, which, on paper, seem completely incompatible! It is the world’s first biotech […]

April 16, 2015 - 2 minutesmins - By Alexandre Lowrey

News and Trends 15 Apr 2015

Synthetic bio: one single Grapefruit to produce one Million liters of Juice

The Austrian Centre of Industrial Biotechnology (acib), using synthetic biology technology, developed a new method to produce Nootkatone, an expensive grapefruit aroma. The biotechnological process uses cheap sugar as substrate for a “turbo-yeast”. The extremely expensive substance is used in soft drinks, pharmaceutical products or even as an insect repellent, and it is found only […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

Heart Metabolics bargain with the FDA for a single Phase III

Heart Metabolics received an agreement letter from the FDA related to the company’s proposed phase III trial Special Protocol Assessment (SPA) request. The FDA has agreed to a single, randomized, pivotal Phase III trial of 350 patients evaluating perhexiline for the treatment of moderate-to-severe hypertrophic cardiomyopathy (HCM). The company, focused on the development of drugs […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Last week, FDA expressed its concerns about AstraZeneca’s treatment for type 2 diabetes, Onglyza. According to Reuters, FDA found “significant or near significant” increase of death risk. However, the agency also admits that the cause of death is multifactorial and could not be directly related to AstraZeneca’s treatment. The drug was developed as a result […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

Will the roads of the future be paved with microalgae?

In contrast to first generation biofuels, where edible plants were suggested to be grown to obtain oil, microalgae raise as a very promising source alternative to fossil fuels. For the first time, they have been used to make bio-bitumen. Some French public institutes (Centre National de la Recherche Scientifique, Université de Nantes, Ecole des Mines de Nantes) in partnership […]

April 15, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 Apr 2015

Novacyt raised €2.2M to accelerate its technology’s launching in China

Novacyt announced a private equity placement financing of €2.2M that will be used to accelerate the launch of NOVAprep into China with its distribution partner Leica Biosystems, now scheduled for Q2 2015. This follows the successful financing of €3.1M in December 2014. This latest financing attracted support from current investors including Alto Invest, and a […]

April 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Apr 2015

Humabs and MedImmune partnership to develop an Influenza A treatment

Medimmune starts phase I clinical trial to investigate an antibody developed under a collaboration with Humabs BioMed for the treatment of influenza A. The novel antibody developed through Humabs’ Cellclone technology will be investigated a trial being conducted by MedImmune, the global biologics research and development arm of AstraZeneca. The investigational antibody, which has broad influenza-neutralizing […]

April 13, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Histalim, already 10 years committed to Histology

The first-in-human Phase I trial for a treatment against glaucoma core

Wilson Therapeutics on its way to cure Wilson disease

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

The challenge of terminal sterilization of Proteins

flash4science, the life science private shopping club

Synthetic bio: one single Grapefruit to produce one Million liters of Juice

Heart Metabolics bargain with the FDA for a single Phase III

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Will the roads of the future be paved with microalgae?

Novacyt raised €2.2M to accelerate its technology’s launching in China

Humabs and MedImmune partnership to develop an Influenza A treatment

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!